EcoDrugPlus

Protein-Serine O-Palmitoleoyltransferase Porcupine-Like

Ensembl ID : ENSSMAG00000003314
Gene Symbol: LOC118316990
2 Cross references
197 Possible Orthologues:

Proteinase-Activated Receptor 1-Like

Ensembl ID : ENSSMAG00000030722
Gene Symbol: LOC118300474
3 Cross references
263 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src-Like

Ensembl ID : ENSSMAG00000010185
Gene Symbol: LOC118309134
2 Cross references
192 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3a

Ensembl ID : ENSSMAG00000019563
Gene Symbol: P2RX3A
3 Cross references
192 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3b

Ensembl ID : ENSSMAG00000015056
Gene Symbol: P2RX3B
1 Cross references
195 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 7

Ensembl ID : ENSSMAG00000016255
Gene Symbol: P2RX7
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSSMAG00000012110
Gene Symbol: P2RY1
3 Cross references
190 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSSMAG00000012234
Gene Symbol: P2RY12
1 Cross references
180 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSSMAG00000018918
Gene Symbol: P2RY6
3 Cross references
182 Possible Orthologues:

Receptor (Tnfrsf)-Interacting Serine-Threonine Kinase 1, Like

Ensembl ID : ENSSMAG00000020150
Gene Symbol: RIPK1L
1 Cross references
197 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSSMAG00000033979
Gene Symbol: RAMP1
3 Cross references
191 Possible Orthologues:

Receptor Activity-Modifying Protein 1-Like

Ensembl ID : ENSSMAG00000036077
Gene Symbol: LOC118314309
2 Cross references
184 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).